Overview
- The Trump administration's DOJ has filed a motion to dismiss or transfer a lawsuit by Missouri, Idaho, and Kansas challenging FDA deregulation of mifepristone.
- The DOJ contends that the states lack standing and that the Northern District of Texas is an improper venue for the case.
- Sen. Josh Hawley has urged Attorney General Pam Bondi to reconsider defending Biden-era policies that expanded mail-order and telehealth access to mifepristone.
- Anti-abortion leaders, including Kristen Waggoner and Marjorie Dannenfelser, argue that the Biden administration's policies have increased health risks for women and call for stricter regulations.
- Mifepristone, which accounted for 63% of U.S. abortions in 2023, remains a focal point in broader debates over federal regulatory authority and state sovereignty.